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PLgCAINIDE PROVIDES SAFE TSBWY FOR SUPBAVBNTRICULAR 
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Concerns about the safety and efficacy of Clasr IC 
antiarrhythmice have arisen as a result of recent CAST 
data. We reviewed records of 175 can6ccutive patients 
(pte) treated uith flecainide between 7/l/08-7/5/89. 
110 pte with normal or mildly impaired LV function and 
symptomatic aupraventricular tachyarrhythmiae (SVT) 
were identified. 102 of these 110 pte were followed 
for 15 days to 43 months (mean follow-up 14mJ. Cor on- 
ary artery disease was documented in 298 of these pa- 
t fente . Seven patients had a remote myocardial infarc- 
tion (n1) and 1 patient had an 09X within 6 weeks of 
initiating therapy. Plecainide doses tanged from lOO- 
400 mg/day (average dose 244 mg/dayl. Duration of 
therapy was 13 months. Arrhythmia6 treated were atria1 
flbrillation/flutte6 (QOOI, circus movement tachycatdia 
(IQ), an% atrioventricular no%al reentry ( 
ide provided effective antiatrhythmic thsra 
patients. Flecainide wa8 discontinued 
tiente. Rea8on6 for diecontinuation included: 1) CAST 
data (9 pte), 2) treatment failure (6 pts), 3) 8ide 
effect8 (5 pte), 4) successful Bie ablation procedure 
(3 PtS), 5) proarrhythmia (2 pta), 6) unknown reasons 
(13 pte). There were no deaths during the ducation of 
follow-up. 
Conclue ion8 : Plecainide provide8 safe and effective 
treatment of SVI! in patients with normal or milbly 
impaired LV function. 
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THE WAVELElGTH fR II VITRO - A POTENTIALLY 
USEFUL PREDICTOR ARRRYTREIC DRUG EFFECTS OR 
RRENTRY P 
Suzanne Renaer. B.Sc., Stanley Mattel, M.D., F. 
Wontreel Heart Institute, 
East claesification system8 of antiarrhythmic agents 
tare based on changes in APD and $8ax, but there is no 
qusntitative way to relate 8UCh chanEe6 to effect8 on 
reentrent arrhythmias. The wavelength, A, i6 a goo% 
predictor of drug effects on atria1 mrrhythmiae in vivo 
(Circ Ree 58:96,1986), but requires precise xneeeurement 
of refractory period (RP) 8nd conduction velocity (CV). 
Since A (aBPxCV) is the shortest pathlength allowinS 
reentry, decreases in A favour reentry an% increase8 
are antiarrhythmic. We studied the effects of ~168s I 
md III 
~Dx&,,&, 
drrcge on the wewelength 
based on assumed linear relations bet- 
ween APD an% ERP, &88x en% CV. Rate-dependent ChSn- 
Be8 in A an% WLI caused by quinidine (01, lidocaine 
(tl, flecainide (F) and sotalol (S! in canine cardiec 
Purhinje fiber6 were measu g two microelectrodes 
Results: P decreased A E&SD) an% WLI (24k7 
at cycle length (CL) 30 consistent with i 
tachycardia-dependent arrhythmog c action. S increased 
A and WLI at all CL (eg. 19fl 
decreased 1 and ELI 8 
effect8 on 1; these chenges are comPat.ible with the 
beneficiel effects of ~188s III and variable effects of 
IA drugs on reentrant arrhythmias. 
chsngee in k were closely reflecte% by 
all drugs, 
slope ID 
(regression 
-98, intercept = .OZ, r = .92). 
We conclude that the WLI, based only on changes in APD 
and $88x, egrees closlely with directly SBSSU~~% 
ch8nSes in 1, and may be a useful in vitro predictor 
of drug effects on reentrant arrhythmias. 
